ClinicalTrials.gg
RecruitingNCT05763251COUNTUpdated Oct 30, 2026

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

An interventional study of therapy duration in Invasive Candidiasis, sponsored by Arkansas Children's Hospital Research Institute. Recruiting at 22 sites in 2 countries. Open to participants aged 120 Days and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Arkansas Children's Hospital Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 30, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
120 Days and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Candidiasis, Invasive with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Candidiasis, Invasive · United States.

Planned enrollment
4th of 21
420 · median 120
Started
2023
with 1 other
No phase
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Arkansas Children's Hospital Research Institute

Among the 22 studies in Candidiasis, Invasive with a site in United States, this one is the 4th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 with no phase, and was the 21st registered.

Candidiasis, Invasive

65 studies on the registry are indexed under Candidiasis, Invasive; 6 are open to participants now.

Browse Candidiasis, Invasive studies →

Open to participants now

2 of the 22 studies in Candidiasis, Invasive with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Candidiasis, Invasive studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 120 Days and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Candidiasis, Invasive with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare antifungal therapy duration in uncomplicated candidemia. The specific aims are:

  • Compare the desirability of outcome ranking in patients with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy.
  • Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups.

Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Read the detailed description

The primary objective of this study will be addressed with a multi-center open label randomized controlled trial designed to compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy. The secondary objective of this study is an embedded observational biomarker study. This objective will determine if the novel T2Candida® biomarker performed at the time of randomization (i.e. Day 7 of systemic antifungal therapy) will be associated with patient outcomes assessed at Day 14. The results of the T2Candida® biomarker will not be available in real-time and thus will not impact the primary study objective. Eligible patients will be any hospitalized patient at a participating center with uncomplicated candidemia that is older than 120 days and \<25 years of age at time of candidemia onset. Patients need to receive an echinocandin as their primary antifungal therapy for at least three days and continue systemic antifungal therapy (either with an echinocandin or step-down to an azole) for a total of 7 days from their first negative blood culture and have no evidence of metastatic foci of candidemia at the time of randomization. Patients with neutropenia or anticipated to have neutropenia during the study follow-up window will not be eligible. Patients can only be enrolled to the study once. This study population will serve as the source cohort for both study objectives. Patients will be randomized 1:1 to one of two study arms, short-course therapy or standard-course therapy. Patients will be followed for 21 days from the day of randomization (Day 7 to Day 28) to capture primary and secondary outcome measures.

03

Conditions studied

  • Invasive Candidiasis

Browse trials for

04

Who can participate

Ages eligible
120 Days and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 120 days at the time of the first negative blood culture at any participating site;
  2. Candidemia with at least one positive blood culture for any Candida spp;
  3. Receiving/received an echinocandin (caspofungin, micafungin, anidulafungin, or rezafungin) as primary antifungal therapy for candidemia for at least 2 days from day of first negative culture with continuation of uninterrupted systemic antifungal therapy at the time of enrollment);
  4. Sustained clearance of Candida spp. defined as negative blood culture(s) obtained after onset of candidemia and before day of randomization;
  5. Partial or complete clinical response, as defined by published guidelines (Table 5), on or before day of randomization;
  6. Between the onset of qualifying candidemia and randomization, no suspicion of disseminated candidiasis by patient's clinical team or, if deemed clinically necessary, documented negative radiological imaging such as an abdominal ultrasound or abdominal CT scan.

Exclusion criteria

Exclusion Criteria:

  1. Already receiving antifungal therapy for a previously diagnosed systemic invasive fungal disease;
  2. Neutropenic ( \< 500 cells/µl) at the time of enrollment or anticipated to be neutropenic in the week following randomization;
  3. Have an underlying condition that requires them to be on antifungal prophylaxis when not receiving directed therapy for an invasive fungal disease;
  4. Previous enrollment in this trial;
  5. Females of childbearing age with a current pregnancy diagnosis or without a negative pregnancy test for their current admission;
  6. A documented DNR order;
  7. Have an implantable cardiac device (e.g., ventricular assist device, pacemaker)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Short-course therapy

    pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive no additional antifungal therapy

    Other: therapy duration

  • No intervention
    Standard-course therapy

    pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive 7 additional days of systemic antifungal therapy

Interventions

  • Othertherapy duration

    the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy

06

What researchers measure

Primary outcomes

  1. Compare the desirability of outcome ranking (DOOR) in short-course vs standard-course arm

    The primary analysis for the primary objective will compare the DOOR distributions at 7 days from randomization (i.e., outcome assessment on Day 14 from first negative blood culture) between subjects from the two study groups, based on randomized treatment assignments, in accordance with the intention-to-treat principle. The primary analysis will use the DOORs assigned on this day to assess which therapy course is better, short-course or standard-course.

    Time frame: The measures assigned on Day 14 will inform the primary analysis for the primary objective

Secondary outcomes

  1. Compare the DOOR for subjects with a negative vs positive T2 Candida® biomarker at day 7

    The results of the Day 7 T2Candida® biomarker (i.e. detected versus not detected) and the randomization group (i.e. short-course versus standard-course) will allow for the following four subsets of patients: 1. Patient is randomized to short-course group and has a not-detected result for the T2Candida® biomarker at time of randomization; 2. patient is randomized to short-course group and has a detected T2Candida® biomarker at time of randomization; 3. patient is randomized to standard-course group and has a not-detected result for the T2Candida® biomarker at time of randomization; 4. patient is randomized to standard-course group and has a detected T2Candida® biomarker at time of randomization. This analysis will compare the DOOR categories between the first two groups (i.e. short-course and not-detected versus short-course and detected) and then be repeated for the second two groups (i.e. standard-course and not detected versus standard-course and detected).

    Time frame: The DOOR measure on Day 14 will be used for the primary analysis for the secondary objective.

07

Study locations

22 of 22 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2030, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 10, 2023
StartActual
Sep 8, 2023
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2032
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Title Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05763251
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Sep 8, 2023
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Oct 30, 2026

Study contacts

Sarah K Johnson, PhD
Contact
skjohnson@uams.edu
501-364-3057
Sydney Shuster, MPH
Contact
shusters@chop.edu
267-425-1462
Brian Fisher, DO
principal investigator · Children's Hospital of Philadelphia
William J Steinbach, MD
principal investigator · Arkansas Children's Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion